CSF1 and cancer: Neutralization of CSF-1 actions, by treatment with specific anti-CSF-1 (aCSF-1) or anti-CSF-1R antibodies or use of cFMS Receptor Tyrosine Kinase inhibitors, is a useful approach to study CSF-1 function and is considered as a therapeutic option for autoimmune diseases, atherosclerosis and cancer in both animal models and clinical trials (52).